Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alumis Inc. - Common Stock (NQ:ALMS)

26.68 -1.42 (-5.04%)
Streaming Delayed Price Updated: 1:37 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alumis Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ALMS Stock Earnings: Alumis Reported Results for Q2 2024 ↗
Alumis just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
Via Benzinga
News headline image
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' ↗
Target (TGT) stock recommended by Jim Cramer at current price with plans to buy more. Merck (MRK) and Unity Software (U) also discussed. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Alumis to Participate in Upcoming September Investor Conferences
From Alumis Inc.
Via GlobeNewswire
News headline image
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
From Alumis Inc.
Via GlobeNewswire
News headline image
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
From Alumis Inc.
Via GlobeNewswire
News headline image
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation ↗
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
News headline image
Ardent Health Slips After Downsized IPO ↗
Shares of Ardent Health slipped in their trading debut on Thursday after the hospital operator reduced its initial public offering from its proposed size and priced below the marketed range. 
Via Talk Markets
News headline image
Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering ↗
Alumis priced its IPO at $16/share, raising $210 million with 13.13 million shares. Trading begins June 28, 2024. Alumis develops oral therapies for immune-mediated diseases, with its lead candidate... 
Via Benzinga
Topics Initial Public Offering
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.